Resveratrol Isomer Modulation of EndoG for Mitochondrial Inheritance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments are lacking for conditions associated with abnormal persistence of paternal mitochondria, which can lead to developmental defects and diseases such as neurodegeneration and cancer, due to the unaddressed role of mitochondrial endonuclease G (EndoG) in mitochondrial inheritance and cellular processes.

Innovation Solution

The use of resveratrol isomers, specifically cis-resveratrol and trans-resveratrol, or their stabilized derivatives, to modulate the activity of EndoG, either inhibiting or enhancing its function as needed, providing therapeutic benefits for conditions like neurodegeneration and cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If resveratrol is used to treat EndoG-associated diseases, then therapeutic efficacy is improved, but the complexity of selecting and stabilizing specific isomers increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidisomer selection and stabilization complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by transforming resveratrol from a dynamic mixture of isomers into a stabilized form with fixed configuration. This chemical modification locks the molecule in a specific isomeric state, eliminating the need for complex selection processes and ensuring consistent therapeutic activity against EndoG-associated diseases.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent extracts the active isomeric form from the complex mixture of resveratrol isomers. By isolating and stabilizing the specific isomer responsible for EndoG modulation, the invention removes the complexity of dealing with multiple isomers while retaining the essential therapeutic effect.

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If cis-resveratrol is used to inhibit EndoG activity, then neurodegeneration is treated, but the ability to enhance PME is reduced

Engineering Contradiction:

Improveneurodegeneration treatmentVSAvoidPME enhancement capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies the inversion principle by using the opposite isomer (trans-resveratrol) to achieve the opposite effect (PME enhancement) when needed. This allows the treatment to be adapted to different disease states by simply switching between isomers, resolving the contradiction between neurodegeneration treatment and PME enhancement capability.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent achieves multi-functionality by demonstrating that resveratrol isomers can serve different therapeutic purposes: cis-resveratrol for inhibiting EndoG activity in neurodegeneration, and trans-resveratrol for enhancing PME. This universal approach allows a single compound class to address multiple disease mechanisms.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If trans-resveratrol is used to enhance PME, then paternal mitochondrial elimination is improved, but the ability to inhibit EndoG activity is reduced

Engineering Contradiction:

Improvepaternal mitochondrial eliminationVSAvoidEndoG activity inhibition

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies inversion by using cis-resveratrol instead of trans-resveratrol when EndoG activity inhibition is the primary goal. This isomeric switch reverses the effect on EndoG while maintaining the ability to treat diseases through alternative mechanisms.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent applies dynamics by allowing the choice between different isomers based on the specific disease state and therapeutic requirement. The system can dynamically switch between cis- and trans-resveratrol to optimize treatment effectiveness for different conditions.

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Resveratrol isomers effectively treat EndoG-associated diseases by targeting CPS-6, a mitochondrial endonuclease G, thereby regulating paternal mitochondrial elimination and associated diseases, including neurodegeneration and cancer, through specific modulation of EndoG activity.

Implementation Method 1

the invention describes the action of cis- and trans-resveratrol to inhibit or increase the nuclease activity of EndoG, respectively

Methodology Applied

Scientific EffectEnzyme modulation: Enzyme

Implementation Method 2

resveratrol exists as a mixture of trans- and cis-isomers, which can be interconverted by light absorption

Methodology Applied

Scientific EffectLight absorption: Absorption (EM radiation)

Data Source

PatentUS20250346550A1Methods of modulating endonuclease g using resveratrol and its derivatives

Publication Date: 2025.11.13 THE REGENTS OF THE UNIVERSITY OF COLORADO

AI summary

The present invention describes the mechanism and physiological target for resveratrol, and in particular the novel mechanism by which trans- and c/.s-resveratrol isomers show opposite effects in enhancing and inhibiting the nuclease activity of EndoG in vitro and multiple important cellular processes in vivo.